Phaseline

Companies › Bicara Therapeutics

Bicara Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 5 registered trials: 4 Phase 2, 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Ficerafusp alfa (BCA101)
Bispecific antibody targeting EGFR and TGF-β
EGFR, TGFB1Phase 2Metastatic Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Squamous Cell Carcinoma of Head and Neck (SCCHN)Oct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04429542Ficerafusp alfa (BCA101)Phase 1Head and Neck Squamous Cell CarcinomaOncologyOct 2027
NCT07807163Ficerafusp alfa (BCA101)Phase 2Metastatic Head and Neck Squamous Cell CarcinomaOncologyMar 2028
NCT06788990Ficerafusp alfa (BCA101)Phase 2Metastatic Head and Neck Squamous Cell CarcinomaOncologyApr 2028
NCT07465276Ficerafusp alfa (BCA101)Phase 2Head and Neck Squamous Cell Carcinoma (HNSCC)OncologyApr 2028
NCT07529873Ficerafusp alfa (BCA101)Phase 2Squamous Cell Carcinoma of Head and Neck (SCCHN)OncologyApr 2030

From the company's SEC filings

Cash and short-term investments of $442m on 2026-09-30; operating cash outflow about $185m a year; runway about 29 months at that burn, to Feb 2029; 3 of 4 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

EGFR (1) TGFB1 (1)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.